ZA926013B - 1-acylpiperidene compounds - Google Patents

1-acylpiperidene compounds

Info

Publication number
ZA926013B
ZA926013B ZA926013A ZA926013A ZA926013B ZA 926013 B ZA926013 B ZA 926013B ZA 926013 A ZA926013 A ZA 926013A ZA 926013 A ZA926013 A ZA 926013A ZA 926013 B ZA926013 B ZA 926013B
Authority
ZA
South Africa
Prior art keywords
optionally
radical
optionally substituted
alkylene
alkanoyl
Prior art date
Application number
ZA926013A
Other languages
English (en)
Inventor
Walter Schilling
Schilling Walter
Silvio Ofner
Ofner Silvio
Siem J Veenstra
J Veenstra Siem
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA926013B publication Critical patent/ZA926013B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pyridine Compounds (AREA)
ZA926013A 1991-08-12 1992-08-11 1-acylpiperidene compounds ZA926013B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH237491 1991-08-12

Publications (1)

Publication Number Publication Date
ZA926013B true ZA926013B (en) 1993-03-31

Family

ID=4232283

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA926013A ZA926013B (en) 1991-08-12 1992-08-11 1-acylpiperidene compounds

Country Status (23)

Country Link
US (3) US5310743A (no)
EP (1) EP0532456B1 (no)
JP (1) JP3118090B2 (no)
KR (1) KR100261367B1 (no)
AT (1) ATE120456T1 (no)
AU (1) AU660180B2 (no)
CA (1) CA2075684C (no)
DE (1) DE59201771D1 (no)
DK (1) DK0532456T3 (no)
ES (1) ES2070617T3 (no)
FI (1) FI104631B (no)
GR (1) GR3015954T3 (no)
HU (1) HU221305B1 (no)
IL (2) IL102769A (no)
MX (1) MX9204627A (no)
MY (1) MY110227A (no)
NO (2) NO303448B1 (no)
NZ (1) NZ243888A (no)
PH (1) PH29963A (no)
RU (1) RU2114829C1 (no)
SA (1) SA94140632A (no)
TW (1) TW204342B (no)
ZA (1) ZA926013B (no)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69300043T2 (de) * 1992-03-13 1995-05-24 Bio Mega Boehringer Ingelheim Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer.
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
US5656642A (en) * 1993-04-07 1997-08-12 Otsuka Pharmaceutical Co., Ltd. Peripheral vasodilating agent containing piperidine derivative as active ingredient
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
US5883098A (en) * 1993-11-29 1999-03-16 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
WO1996010562A1 (en) * 1994-09-30 1996-04-11 Novartis Ag 1-acyl-4-aliphatylaminopiperidine compounds
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
US5929067A (en) * 1995-02-22 1999-07-27 Novartis Ag 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
RU2156250C2 (ru) * 1995-04-24 2000-09-20 Новартис Аг Производные хромона, способ их получения и фармацевтическая композиция
US6288225B1 (en) 1996-05-09 2001-09-11 Pfizer Inc Substituted benzolactam compounds as substance P antagonists
JP3042894B2 (ja) * 1995-07-07 2000-05-22 ファイザー製薬株式会社 サブスタンスｐアンタゴニストとしての置換ベンゾラクタム化合物
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
EP0873117A4 (en) * 1995-11-13 1999-02-24 Smithkline Beecham Corp HEMOREGULATORY CONNECTIONS
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
IL123655A (en) 1996-04-12 2001-03-19 Janssen Pharmaceutica Nv Substituted tetracyclic tetrahydrofuran derivatives and pharmaceutical compositions containing them
AU2898297A (en) * 1996-05-24 1998-01-05 Novartis Ag Use of substance p antagonists for treating social phobia
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
EA004037B1 (ru) * 1996-09-10 2003-12-25 Др. Карл Томэ ГмбХ Модифицированные аминокислоты и лекарственное средство на их основе
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
AU732633B2 (en) * 1996-12-02 2001-04-26 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating schizophrenic disorders
EP0977572A1 (en) * 1997-04-24 2000-02-09 Merck Sharp & Dohme Ltd. Use of nk-1 receptor antagonists for treating eating disorders
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
AR018376A1 (es) * 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
FR2780057B1 (fr) * 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
EP1107744B1 (en) * 1998-08-25 2003-04-23 Novartis AG Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
HUP0201443A3 (en) * 1999-05-21 2005-09-28 Pfizer Prod Inc 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives and pharmaceutical compositions containing them
GB9917408D0 (en) * 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
AU2399601A (en) * 1999-12-21 2001-07-03 Takeda Chemical Industries Ltd. Novel tachykinin-like polypeptides and use thereof
EP1299393A2 (en) 2000-07-11 2003-04-09 Bristol-Myers Squibb Pharma Company 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
MXPA03000708A (es) 2000-07-26 2003-06-04 Smithkline Beecham Plc Aminopiperidin quinolinas y sus analogos azaisostericos con actividad antibacteriana.
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
WO2002068409A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
AU2002338334B8 (en) 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
KR100668231B1 (ko) * 2001-12-03 2007-01-16 에프. 호프만-라 로슈 아게 무스카린 수용체 길항제로서의 아미노테트랄린 유도체
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
EP1470131A2 (en) * 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
TWI283241B (en) * 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
JP2004285038A (ja) * 2002-05-31 2004-10-14 Takeda Chem Ind Ltd ピペリジン誘導体、その製造法および用途
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds
ES2310260T3 (es) 2002-12-23 2009-01-01 Janssen Pharmaceutica Nv Derivados sustituidos de 4-(4-piperidin-4-il-piperazin-1-il)-azepan y su uso como antagonistas de la neuroquinina.
JP4660199B2 (ja) 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
JO2485B1 (en) 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
US7390905B2 (en) 2003-11-28 2008-06-24 Mitsubishi Tanabe Pharma Corporation Piperidine compound and process for preparing the same
MY142362A (en) 2004-01-29 2010-11-30 Otsuka Pharma Co Ltd Pharmaceutical composition for promoting angiogenesis
US7232831B2 (en) * 2004-03-22 2007-06-19 Mediquest Therapeutics, Inc. Tetrahydro-β-carboline compounds and use thereof
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8604200B2 (en) 2005-03-08 2013-12-10 Janssen Pharmaceutica N.V. Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0607532D0 (en) * 2006-04-13 2006-05-24 Novartis Ag Organic compounds
MX2009000646A (es) * 2006-07-20 2009-01-29 Novartis Ag Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp).
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010072599A1 (en) * 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Dihydropyridone ureas as p2x7 modulators
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
EP2429293B1 (en) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2015008196A (es) 2012-12-20 2015-09-16 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
EP3706747A4 (en) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
JP2024503851A (ja) * 2021-01-14 2024-01-29 アレクシオン ファーマシューティカルズ， インコーポレイテッド 大員環補体因子ｂ阻害剤
AU2022292554A1 (en) 2021-06-14 2024-01-04 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5145967A (en) * 1989-04-20 1992-09-08 Anaquest, Inc. Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5126455A (en) * 1989-12-13 1992-06-30 Glaxo Inc. Preparation of substituted alkali metal piperidine-4-carboxylates
PL168236B1 (pl) * 1990-05-31 1996-01-31 Pfizer Sposób wytwarzania podstawionych piperydyn PL PL PL
CA2084193C (en) * 1990-06-01 1998-04-07 John A. Lowe, Iii 3-amino-2-aryl quinuclidines
BR9106905A (pt) * 1990-09-28 1993-08-17 Pfizer Analogos de anel condensado de heterociclos nao aromaticos contendo nitrogenio

Also Published As

Publication number Publication date
SA94140632A (ar) 2005-12-03
KR100261367B1 (ko) 2000-07-01
FI923575A (fi) 1993-02-13
HUT67088A (en) 1995-01-30
KR930004297A (ko) 1993-03-22
NO923123L (no) 1993-02-15
CA2075684A1 (en) 1993-02-13
JPH07196649A (ja) 1995-08-01
RU2114829C1 (ru) 1998-07-10
AU2096592A (en) 1993-03-04
US5310743A (en) 1994-05-10
ES2070617T3 (es) 1995-06-01
TW204342B (no) 1993-04-21
NO973117L (no) 1993-02-15
EP0532456B1 (de) 1995-03-29
NO303448B1 (no) 1998-07-13
IL118750A0 (en) 1996-10-16
MX9204627A (es) 1993-04-01
FI104631B (fi) 2000-03-15
CA2075684C (en) 2003-01-07
FI923575A0 (fi) 1992-08-10
IL102769A (en) 1999-01-26
AU660180B2 (en) 1995-06-15
HU221305B1 (en) 2002-09-28
ATE120456T1 (de) 1995-04-15
NO973117D0 (no) 1997-07-04
DK0532456T3 (da) 1995-06-12
MY110227A (en) 1998-03-31
EP0532456A1 (de) 1993-03-17
HU9202615D0 (en) 1992-10-28
GR3015954T3 (en) 1995-07-31
IL102769A0 (en) 1993-01-31
DE59201771D1 (de) 1995-05-04
NZ243888A (en) 1996-03-26
US5541195A (en) 1996-07-30
JP3118090B2 (ja) 2000-12-18
PH29963A (en) 1996-09-25
NO923123D0 (no) 1992-08-11
US5646144A (en) 1997-07-08

Similar Documents

Publication Publication Date Title
IL102769A0 (en) 1-acylpiperidine compounds
DK0463560T3 (da) Nye antiepileptiske midler
CA2044746A1 (en) Polypeptide compound and a process for preparation thereof
NZ332608A (en) alkyl 17-alpha-dichloroacetoxy-11- beta-hydroxy-androsta-1,4-diene-3-one-17-beta-carboxylates and medicaments
KR960013370A (ko) 트리글리세리드 과다 방지 조성물
ES8207124A1 (es) Un procedimiento para la preparacion de derivados de aminas secundarias.
HUT38097A (en) Process for preparing substituted benzopyrans and pharmaceutical compositions containing them as active substances
AU571434B2 (en) Ethers and oxime ethers of alkylaminoalcohols
AU571841B2 (en) Carbacyclin pharmaceutical preparations
CA2127067A1 (fr) Derives d'acide phosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
ES8607972A1 (es) Procedimiento para la obtencion de compuestos heterociclicos penemicos
ES435361A1 (es) Un metodo para la preparacion de nuevos esteres alcohilicosde aminoacidos.
ATE92461T1 (de) Gegen die zerebrale insuffizienz wirksame verbindungen.
RU2053228C1 (ru) Производные пептидов, способ их получения, фармацевтическая композиция, ингибирующая эластазу человеческих лейкоцитов
TH29704B (th) ไพราโซโลไพริมิดิน